We speculated that epigenetic changes during ADM in the Kras pathway, whose upregulation is a defining feature of pancreatic cancer, might reflect neoplastic-like activation of Kras even without a Kras mutation. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.